879127-16-9

Basic information

• Product Name: Aurora Kinase Inhibitor III
• Synonyms: N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide;Aurora Kinase Inhibitor III;Cyclopropanecarboxylic acid {3-[4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino]-phenyl}-amide
• CAS NO: 879127-16-9
• Molecular Formula: C21H18F3N5O
• Molecular Weight: 413.401
• Mol File: 879127-16-9.mol

Chemical Properties

• Appearance: white/
• Density: 1.456±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: H2O:
• PKA: 14.51±0.70(Predicted)
• CAS DataBase Reference: Aurora Kinase Inhibitor III(CAS DataBase Reference)
• NIST Chemistry Reference: Aurora Kinase Inhibitor III(879127-16-9)
• EPA Substance Registry System: Aurora Kinase Inhibitor III(879127-16-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 879127-16-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Aurora Kinase Inhibitor III is used as a research tool for studying the role of Aurora kinases in various cellular processes and diseases. Its application is particularly valuable in the investigation of Aurora A kinase, which plays a crucial role in cell division and has been implicated in the development of several cancers.
Used in Cancer Research:
Aurora Kinase Inhibitor III is utilized as a potential therapeutic agent for the treatment of cancer. By inhibiting Aurora A kinase, it can help control unregulated cell division and may contribute to the suppression of tumor growth. The inhibitory effects on other kinases at higher concentrations also provide avenues for exploring its potential in targeting multiple pathways involved in cancer progression.
Used in Drug Development:
In the drug development industry, Aurora Kinase Inhibitor III serves as a lead compound for the design and synthesis of more selective and potent Aurora kinase inhibitors. This can lead to the creation of new drugs with improved efficacy and reduced side effects, ultimately benefiting cancer patients.
Used in Cell Biology Research:
Aurora Kinase Inhibitor III is employed as a biochemical reagent in cell biology research to understand the mechanisms of cell division, particularly the role of Aurora kinases in the regulation of mitotic events. This knowledge can be instrumental in developing targeted therapies for conditions related to abnormal cell division.

Biochem/physiol Actions

Target IC50: 42 nM against Aurora A; 131, 386, 591, and 887 nM, against Lck, Bmx, IGF-1R, and Syk , respectively

Upstream product

• 879127-21-6 N-(3-aminophenyl)-cyclopropanecarboxamide 
• 879127-23-8 (2-chloro-pyrimidin-4-yl)-(3-trifluoromethyl-phenyl)-amine 
• 98-16-8 3-trifluoromethylaniline 
• 99-09-2 3-nitro-aniline 
• 101946-39-8 N-(3-nitrophenyl) cyclopropanecarboxamide 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di

Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library

The epidermal growth factor receptor (EGFR) tyrosine kinase was one of the first receptor tyrosine kinases to be targeted for drug development by the pharmaceutical industry due to its ubiquitous overexpression in a variety of tumors. Despite the validati